Keywords: topiagen/nicox, discontinue, copd, drug, due, poor, results

Topiagen/NicOx discontinue COPD drug

Article | 15 January 2009

Print This

Due to poor results from a Phase IIa study of Topiagen Pharmaceuticals' TPI 1020 in chronic obstructive pulmonary disease, the US ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in